Related Experiment Video

Updated: Dec 23, 2025

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

14.0K

Multifaceted transforming growth factor-beta (TGFβ) signalling in glioblastoma

Joanna L Birch1, Barry J Coull2, Lindsay C Spender3

  • 1CRUK Beatson Institute, Glasgow, UK.

Cellular Signalling
|April 23, 2020
PubMed

Insights

Glioblastoma (GBM) is a deadly brain cancer with poor treatment outcomes. Targeting the TGFβ signaling pathway, implicated in GBM development, offers a promising therapeutic strategy for improved patient survival.

Area of Science:

  • Neuro-oncology
  • Cancer Biology
  • Molecular Signaling

Background:

  • Glioblastoma (GBM) is an aggressive primary brain cancer with limited treatment options and poor patient prognosis.
  • Transforming Growth Factor-beta (TGFβ) is a cytokine crucial for tissue homeostasis and immune responses.
  • TGFβ signaling pathway dysregulation is implicated in the development and progression of various cancers, including GBM.

Purpose of the Study:

  • To review the role of TGFβ signaling in GBM development and progression.
  • To explore potential therapeutic strategies targeting TGFβ signaling in GBM.

Main Methods:

  • Literature review of studies on TGFβ signaling in GBM.
  • Analysis of TGFβ pathway mechanisms in cancer biology.
  • Examination of therapeutic approaches targeting TGFβ.

Main Results:

  • TGFβ signaling plays a significant role in GBM pathogenesis.
  • Targeting TGFβ pathways presents a viable therapeutic avenue for GBM.
  • Decorin, a TGFβ binding protein, is highlighted as a potential therapeutic agent.

Conclusions:

  • Dysfunctional TGFβ signaling is a key driver in GBM.
  • Targeting TGFβ signaling pathways, including using Decorin, represents a promising strategy for novel GBM therapies.
  • Further research into TGFβ-targeted therapies is warranted to improve patient outcomes in GBM.
Keywords:
DecorinGlioblastomaTransforming growth factor beta

More Related Videos

Translational Orthotopic Models of Glioblastoma Multiforme07:37

Translational Orthotopic Models of Glioblastoma Multiforme

Published on: February 17, 2023

3.4K
Co-culture of Glioblastoma Stem-like Cells on Patterned Neurons to Study Migration and Cellular Interactions10:08

Co-culture of Glioblastoma Stem-like Cells on Patterned Neurons to Study Migration and Cellular Interactions

Published on: February 24, 2021

6.6K

Related Concept Videos

TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.3K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K